Grail Stock
Blood-sampling device
Sign up today and learn more about Grail Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Grail Stock
Grail develops a pan-cancer screening test designed to detect cancer early. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
Investors
6 Dimensions Capital
Ally Bridge Group
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Blue Pool Capital
Hillhouse Capital Group
Market Kurly, Swiggy, Grail, Traveloka, Coalition, Nature's Fynd, Airwallex, Omio
Funding History
| January 2016 | $85.0M |
|---|---|
| November 2017 | $1.2B |
| May 2018 | $300M |
| November 2019 | $392M |
Management
Chief Executive Officer
Hans Bishop
Chief Operating Officer & Chief Financial Officer
Matthew Young
Chief Scientific Officer
Alex Aravanis
Press
fiercebiotech - Feb, 18 2020
Grail kicks off its first study to provide doctors with real-world results from its multi-cancer blood testTechCrunch - Nov, 1 2017
Early cancer-detection startup Grail is reportedly trying to raise more moneyTechCrunch - Jan, 6 2017
Grail is raising at least $1 billion to fund its early cancer screening testEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
